Polaris Greystone Financial Group LLC raised its position in shares of Stryker Co. (NYSE:SYK) by 0.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 112,871 shares of the medical technology company’s stock after buying an additional 347 shares during the quarter. Stryker accounts for 1.9% of Polaris Greystone Financial Group LLC’s portfolio, making the stock its 23rd largest position. Polaris Greystone Financial Group LLC’s holdings in Stryker were worth $23,601,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of SYK. Massey Quick Simon & CO. LLC purchased a new stake in shares of Stryker in the second quarter worth approximately $27,000. Ossiam purchased a new stake in shares of Stryker in the second quarter worth approximately $33,000. Stonebridge Capital Advisors LLC purchased a new stake in shares of Stryker in the second quarter worth approximately $39,000. Webster Bank N. A. lifted its position in shares of Stryker by 300.0% in the second quarter. Webster Bank N. A. now owns 200 shares of the medical technology company’s stock worth $41,000 after purchasing an additional 150 shares in the last quarter. Finally, Westside Investment Management Inc. purchased a new stake in shares of Stryker in the second quarter worth approximately $47,000. 72.95% of the stock is owned by institutional investors.

In related news, VP M Kathryn Fink sold 28,690 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $220.97, for a total value of $6,339,629.30. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Timothy J. Scannell sold 4,666 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $218.51, for a total value of $1,019,567.66. The disclosure for this sale can be found here. Insiders sold 51,637 shares of company stock worth $11,240,206 in the last 90 days. 7.20% of the stock is currently owned by corporate insiders.

NYSE:SYK traded up $1.38 during mid-day trading on Wednesday, reaching $209.26. The stock had a trading volume of 59,617 shares, compared to its average volume of 1,201,179. The business’s 50 day moving average is $217.38 and its 200 day moving average is $202.75. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $223.45. The stock has a market cap of $80.62 billion, a P/E ratio of 28.63, a PEG ratio of 2.61 and a beta of 0.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The firm had revenue of $3.65 billion for the quarter, compared to the consensus estimate of $3.60 billion. During the same quarter in the prior year, the company posted $1.76 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Equities analysts expect that Stryker Co. will post 8.21 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.08 dividend on an annualized basis and a yield of 0.99%. Stryker’s dividend payout ratio is currently 28.45%.

A number of analysts have recently issued reports on the stock. Robert W. Baird increased their price target on shares of Stryker from $206.00 to $239.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 price target for the company in a research report on Monday, July 29th. Barclays set a $226.00 price target on shares of Stryker and gave the stock a “buy” rating in a research report on Friday, July 26th. BMO Capital Markets set a $216.00 price target on shares of Stryker and gave the stock a “hold” rating in a research report on Friday, July 26th. Finally, Canaccord Genuity increased their price target on shares of Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Six equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Stryker presently has an average rating of “Buy” and a consensus target price of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: What is a Fibonacci Channel?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.